CRSP has been the subject of a number of other reports. Canaccord Genuity raised their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Roth Capital raised their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Chardan Capital reissued a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Finally, Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $71.38.
Shares of Crispr Therapeutics stock traded down $4.17 on Friday, hitting $61.84. The company had a trading volume of 1,473,420 shares, compared to its average volume of 720,811. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -17.98 and a beta of 3.30. The stock has a 50 day moving average of $64.60 and a 200-day moving average of $50.48. Crispr Therapeutics has a 1 year low of $27.11 and a 1 year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Equities analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 in the last three months. 21.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BSW Wealth Partners purchased a new stake in Crispr Therapeutics during the second quarter valued at about $39,000. Balyasny Asset Management LLC purchased a new stake in Crispr Therapeutics during the second quarter valued at about $5,165,000. BNP Paribas Arbitrage SA purchased a new stake in Crispr Therapeutics during the second quarter valued at about $41,000. Bank of New York Mellon Corp increased its holdings in shares of Crispr Therapeutics by 116.5% in the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after buying an additional 17,810 shares during the period. Finally, First Trust Advisors LP purchased a new position in shares of Crispr Therapeutics in the third quarter worth about $987,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is meant by buying and selling pressure?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.